CA2282727A1 - Cell surface molecule mediating cell adhesion and signal transmission - Google Patents

Cell surface molecule mediating cell adhesion and signal transmission Download PDF

Info

Publication number
CA2282727A1
CA2282727A1 CA002282727A CA2282727A CA2282727A1 CA 2282727 A1 CA2282727 A1 CA 2282727A1 CA 002282727 A CA002282727 A CA 002282727A CA 2282727 A CA2282727 A CA 2282727A CA 2282727 A1 CA2282727 A1 CA 2282727A1
Authority
CA
Canada
Prior art keywords
cell surface
surface molecule
signal transmission
surface molecules
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002282727A
Other languages
French (fr)
Other versions
CA2282727C (en
Inventor
Takuya Tamatani
Katsunari Tezuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Takuya Tamatani
Katsunari Tezuka
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26403281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2282727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takuya Tamatani, Katsunari Tezuka, Japan Tobacco Inc. filed Critical Takuya Tamatani
Publication of CA2282727A1 publication Critical patent/CA2282727A1/en
Application granted granted Critical
Publication of CA2282727C publication Critical patent/CA2282727C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion.
Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
CA002282727A 1997-02-27 1998-02-27 Cell surface molecule mediating cell adhesion and signal transmission Expired - Fee Related CA2282727C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6229097 1997-02-27
JP9/62290 1997-02-27
JP06221798A JP3521382B2 (en) 1997-02-27 1998-02-26 Cell surface molecules that mediate cell-cell adhesion and signal transduction
JP10-62217 1998-02-26
PCT/JP1998/000837 WO1998038216A1 (en) 1997-02-27 1998-02-27 Cell surface molecule mediating cell adhesion and signal transmission

Publications (2)

Publication Number Publication Date
CA2282727A1 true CA2282727A1 (en) 1998-09-03
CA2282727C CA2282727C (en) 2009-06-16

Family

ID=26403281

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002282727A Expired - Fee Related CA2282727C (en) 1997-02-27 1998-02-27 Cell surface molecule mediating cell adhesion and signal transmission

Country Status (20)

Country Link
US (10) US7030225B1 (en)
EP (2) EP0984023B9 (en)
JP (1) JP3521382B2 (en)
KR (1) KR100349388B1 (en)
CN (3) CN100400546C (en)
AT (1) ATE360645T1 (en)
AU (1) AU732378B2 (en)
BR (1) BR9807788B1 (en)
CA (1) CA2282727C (en)
DE (1) DE69837658T2 (en)
DK (1) DK0984023T3 (en)
ES (1) ES2285763T3 (en)
HK (2) HK1026433A1 (en)
ID (1) ID23386A (en)
IL (3) IL131584A0 (en)
NO (3) NO327500B1 (en)
NZ (1) NZ337425A (en)
PT (1) PT984023E (en)
SI (1) SI0984023T1 (en)
WO (1) WO1998038216A1 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
DE19821060A1 (en) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
WO1999015553A2 (en) * 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
CA2640956C (en) * 1999-02-03 2012-07-03 Amgen Inc. B7rp-1 polypeptides
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
WO2001008700A1 (en) 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP4737905B2 (en) 1999-09-21 2011-08-03 ジェネティクス インスティテュート，エルエルシー GL50 molecules and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP3597140B2 (en) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP3543966B2 (en) * 2000-05-18 2004-07-21 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory transfer molecule AILIM and its pharmaceutical use
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU6346601A (en) * 2000-05-26 2001-12-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
WO2002074803A2 (en) * 2001-01-16 2002-09-26 Bayer Aktiengesellschaft Regulation of human icos v protein
CA2429397C (en) 2001-01-26 2014-06-03 Commonwealth Scientific And Industrial Research Organisation Methods and means for producing efficient silencing construct using recombinational cloning
JP4212278B2 (en) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
MXPA03008959A (en) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, a receptor for b7-4, and uses therefor.
US20050085627A1 (en) * 2001-06-21 2005-04-21 Youming Zhang Atopy
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
ES2442386T3 (en) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo.
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2031062B1 (en) 2006-06-07 2018-10-24 The University of Tokyo Dna encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity
CN101677853B (en) 2007-05-30 2012-04-18 Hoya株式会社 Intraocular lens inserting tool
JP5236638B2 (en) 2007-05-30 2013-07-17 Ｈｏｙａ株式会社 Intraocular lens insertion device
WO2009001158A1 (en) * 2007-06-22 2008-12-31 Nokia Corporation An antenna arrangement
JP5086713B2 (en) 2007-07-11 2012-11-28 Ｈｏｙａ株式会社 Intraocular lens insertion device
WO2009069546A1 (en) 2007-11-26 2009-06-04 Japan Science And Technology Agency Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
EP3530672A1 (en) 2008-09-26 2019-08-28 Dana Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
JPWO2011007747A1 (en) 2009-07-16 2012-12-27 株式会社糖鎖工学研究所 Glycosylated AILIM extracellular domain and method for producing the same
US20130042873A1 (en) 2010-03-09 2013-02-21 Klaus Bechgaard Contraceptive device
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
LT2925350T (en) 2012-12-03 2019-04-10 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EP3004877A4 (en) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
ITUB20151014A1 (en) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro B7H RECEPTOR LIGANDS IN THE TREATMENT OF OSTEOPENIA AND OSTEOPOROSIS
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109689688B (en) 2016-08-09 2023-06-13 科马布有限公司 anti-ICOS antibodies
CN117701604A (en) 2016-09-02 2024-03-15 学校法人庆应义塾 Visual function regenerating agent or visual function decreasing preventive agent
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
TW202003565A (en) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 Antibodies against MICA and/or MICB and uses thereof
KR20230031981A (en) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
CA3154358A1 (en) 2019-09-13 2021-03-18 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2023538955A (en) 2020-08-31 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and immunotherapy
JPWO2022059736A1 (en) 2020-09-17 2022-03-24
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3201348A1 (en) 2020-12-28 2022-07-07 Masano HUANG Antibody compositions and methods of use thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US164697A (en) * 1875-06-22 Improvement in cloth-steaming machines
US182667A (en) * 1876-09-26 Improvement in flue-stoppers
US177191A (en) * 1876-05-09 Improvement in lamps
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
SE8801537D0 (en) * 1988-04-26 1988-04-26 Ellco Food Ab CELL CULTURE MEDIUM AND PROCEDURES FOR ITS PREPARATION
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5504126A (en) * 1991-11-07 1996-04-02 Safas Corporation Mineral-like coating and methods of using same
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
DE69714966T2 (en) 1996-01-23 2003-04-24 Genentech Inc ANTIBODIES AGAINST CD 18 FOR USE AGAINST BRAIN SHOCK
AR009952A1 (en) 1996-09-18 2000-05-17 Zetesis Spa USE OF PROTEINS AS AGENTS AGAINST AUTOIMMUNE DISEASES.
ATE453406T1 (en) 1996-11-08 2010-01-15 Biogen Idec Inc IDENTIFICATION OF BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN COSTIMULATORY ANTIGENS B7.1 (CD80) AND B7.2 (CD28)
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
WO1999015553A2 (en) * 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
DE19821060A1 (en) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
JPH11228442A (en) 1998-02-09 1999-08-24 Cypros Pharmaceut Corp Use of fructose diphosphate for reducing cyclosporin dose after organ transplantation
JP2000154151A (en) 1998-09-14 2000-06-06 Kyo Jo Immunosuppressant
AU1102000A (en) 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
CA2640956C (en) 1999-02-03 2012-07-03 Amgen Inc. B7rp-1 polypeptides
WO2000067788A2 (en) 1999-05-06 2000-11-16 Genetics Institute, Inc. Use of soluble costimulatory molecules to enhance immune responses
WO2001008700A1 (en) 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
AU6458400A (en) 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP3871503B2 (en) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP4737905B2 (en) 1999-09-21 2011-08-03 ジェネティクス インスティテュート，エルエルシー GL50 molecules and uses thereof
CA2386641A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 32 human secreted proteins
AU2001245396A1 (en) 2000-03-02 2001-09-12 Mayo Foundation For Medical Education And Research Hb7-h2, a novel co-stimulatory molecule
JP3597140B2 (en) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
MXPA03004578A (en) 2000-11-28 2004-05-05 Amgen Inc Novel polypeptides involved in immune response.
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
WO2004003544A1 (en) * 2002-06-26 2004-01-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders

Also Published As

Publication number Publication date
SI0984023T1 (en) 2007-08-31
US7247612B2 (en) 2007-07-24
NO994146D0 (en) 1999-08-26
WO1998038216A1 (en) 1998-09-03
BR9807788A (en) 2000-02-15
CA2282727C (en) 2009-06-16
KR100349388B1 (en) 2002-08-22
US20040229788A1 (en) 2004-11-18
US20040151669A1 (en) 2004-08-05
CN1253567A (en) 2000-05-17
AU732378B2 (en) 2001-04-26
EP0984023A4 (en) 2001-10-31
NO20092369L (en) 1999-10-27
EP1502920A2 (en) 2005-02-02
BR9807788B1 (en) 2010-11-16
EP0984023B1 (en) 2007-04-25
NO327500B1 (en) 2009-07-20
ES2285763T3 (en) 2007-11-16
JPH1129599A (en) 1999-02-02
US20120003231A1 (en) 2012-01-05
ID23386A (en) 2000-04-20
HK1026433A1 (en) 2000-12-15
HK1079240A1 (en) 2006-03-31
IL131584A (en) 2010-06-30
EP0984023B9 (en) 2008-04-16
DE69837658T2 (en) 2007-12-27
JP3521382B2 (en) 2004-04-19
US20030083472A1 (en) 2003-05-01
US20040146506A1 (en) 2004-07-29
US7279560B2 (en) 2007-10-09
EP0984023A1 (en) 2000-03-08
US7259147B2 (en) 2007-08-21
NZ337425A (en) 2001-04-27
US20080248031A1 (en) 2008-10-09
CN1618811A (en) 2005-05-25
CN1221569C (en) 2005-10-05
US7932358B2 (en) 2011-04-26
US7196175B2 (en) 2007-03-27
DE69837658D1 (en) 2007-06-06
US7030225B1 (en) 2006-04-18
PT984023E (en) 2007-07-19
NO994146L (en) 1999-10-27
AU6118598A (en) 1998-09-18
US7294473B2 (en) 2007-11-13
CN100400546C (en) 2008-07-09
DK0984023T3 (en) 2007-07-09
ATE360645T1 (en) 2007-05-15
IL131584A0 (en) 2001-01-28
EP1502920A3 (en) 2005-02-09
US20040151720A1 (en) 2004-08-05
NO331064B1 (en) 2011-09-26
US8389690B2 (en) 2013-03-05
NO20073155L (en) 1999-10-27
KR20000075761A (en) 2000-12-26
US20040120945A1 (en) 2004-06-24
US20040073012A1 (en) 2004-04-15
CN1624115A (en) 2005-06-08
CN1293190C (en) 2007-01-03
EP1502920B1 (en) 2015-09-09
IL206603A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CA2282727A1 (en) Cell surface molecule mediating cell adhesion and signal transmission
AU5665696A (en) Novel methods for the assay of troponin i and t and complexe s of troponin i and t and selection of antibodies for use in immunoassays
AU5752696A (en) Dna binding antibodies
AU6031094A (en) Sensitive nucleic acid sandwich hybridization assays and kits
AU5551796A (en) Sample preprocessor
AU1141597A (en) Electronically-solid-phase assay biomolecules
AU7247896A (en) Protein signature analysis
AU8388098A (en) Assays for diagnosis of thrombophilic disease
AU3399295A (en) Method of detecting autoantibody present in the serum of reumatic
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
AU1448295A (en) Assay employing both protein and antibody
AU679370B2 (en) Interleukin 4 signal transducers and binding assays
AU4606196A (en) Assay, receptor proteins and ligands
AU678952B2 (en) Multi-element battery
AU4929996A (en) Interleukin-2 signal transducers and binding assays
AU1110297A (en) Novel dnas, novel polypeptides and novel antibodies
AU3444499A (en) Monoclonal antibody 3-6-a specific to surface of dendritic cells among the peripheral blood leukocytes
AU3902997A (en) Regenerable biosensor using total internal reflection fluorescence with electrochemical control
AU5137698A (en) Novel dna, novel protein, and novel antibody
AU3079895A (en) Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
AU1997895A (en) Ion-capture reagents and methods for performing binding assays
AU2793297A (en) Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same
AU6663896A (en) Broad specificity antibodies
AU7543594A (en) Assaying biological samples
AU3249395A (en) Portfolio performance analysis system

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160229